Antitumor Effects Generated by pNGVL4a-Sig/E7 (detox)/HSP70 DNA Vaccine Administered Through Gene Gun, Biojector and Syringe

DNA vaccines have emerged as an attractive approach for antigen-specific cancer immunotherapy. We have previously linked Mycobacterium tuberculosis heat shock protein 70 (HSP70) to human papillomavirus type 16 (HPV-16) E7 in the context of a DNA vaccine. Vaccination with DNA encoding E7/HSP70 has generated a dramatic increase of E7-specific CD8+ T cell precursors and a strong anti-tumor effect against E7-expressing tumor (TC-1) in vaccinated mice. The success of our strategy has led to two Phase I/II clinical trial proposals in patients with HPV-16 associated high-grade squamous intraepithelial lesion (HSIL) of the cervix and in patients with advanced HPV-associated head and neck squamous cell carcinoma (HNSCC). To translate our HPV DNA vaccines into the clinical domain, the efficacy of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and of various routes of administrations were assessed in mice. Our results indicated that pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine, administered via various techniques, generated the highest number of E7-specific CD8+ T cells. Description (Set) Proposed Use (Set) The vaccine can be used for control of HPV type 16 infection and associated neoplasms. The vaccine enhancement strategy described could potentially be used for the control of other tumors and/or infectious diseases. Patent (Set) WO 04/098526

Inventor(s): Wu, T.C.

Type of Offer: Licensing



« More Pharmaceutical Patents
« More Medical Patents

---